21168-73-0 Usage
Uses
Used in Pharmaceutical Industry:
1-(2-Hydroxyethyl)piperidine-4-carbonitrile is used as an intermediate compound for the synthesis of antihistamines, antipsychotics, and cardiovascular drugs. Its unique structure allows for the development of new therapeutic agents with improved efficacy and safety profiles.
Used in Agrochemical Industry:
HEPC is used as a key component in the production of agrochemicals, contributing to the development of innovative and effective crop protection products.
Used in Specialty Chemicals Industry:
1-(2-Hydroxyethyl)piperidine-4-carbonitrile is utilized as a versatile intermediate in the manufacturing of specialty chemicals, including fine chemicals and research reagents. Its unique properties enable the creation of novel organic compounds and complex chemical structures for various applications.
Used in Research and Development:
HEPC serves as a crucial building block in the development of new organic compounds and complex chemical structures, driving advancements in chemical research and innovation.
Check Digit Verification of cas no
The CAS Registry Mumber 21168-73-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,1,6 and 8 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 21168-73:
(7*2)+(6*1)+(5*1)+(4*6)+(3*8)+(2*7)+(1*3)=90
90 % 10 = 0
So 21168-73-0 is a valid CAS Registry Number.
21168-73-0Relevant academic research and scientific papers
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
-
Page/Page column 143; 144, (2016/09/13)
The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
HETEROCYCLIC PROTEIN KINASE INHIBITORS
-
Paragraph 00347; 00348, (2013/03/26)
The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
